136 related articles for article (PubMed ID: 17382019)
21. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
[TBL] [Abstract][Full Text] [Related]
23. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
24. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
27. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
28. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
29. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
30. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
31. Imatinib and the treatment of fibrosis: recent trials and tribulations.
Gordon J; Spiera R
Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
[TBL] [Abstract][Full Text] [Related]
32. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.
Brazzelli V; Grasso V; Borroni G
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1471-80. PubMed ID: 23611501
[TBL] [Abstract][Full Text] [Related]
33. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
[TBL] [Abstract][Full Text] [Related]
34. Imatinib in neurofibromatosis type 2.
Lim S; de Souza P
BMJ Case Rep; 2013 Jul; 2013():. PubMed ID: 23839611
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on the development of imatinib and the future of cancer research.
Druker BJ
Nat Med; 2009 Oct; 15(10):1149-52. PubMed ID: 19812576
[No Abstract] [Full Text] [Related]
36. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
[No Abstract] [Full Text] [Related]
37. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.
Adenis A; Bouché O; Bertucci F; Kalbacher E; Fournier C; Cassier P; Collard O; Bay JO; Italiano A; Chevreau C; Clisant S; Kramar A; Blay JY; Penel N
Med Oncol; 2012 Dec; 29(4):3003-8. PubMed ID: 22447483
[TBL] [Abstract][Full Text] [Related]
38. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
Blanchard Z; Mullins N; Ellipeddi P; Lage JM; McKinney S; El-Etriby R; Zhang X; Isokpehi R; Hernandez B; Elshamy WM
PLoS One; 2014; 9(4):e95663. PubMed ID: 24789045
[TBL] [Abstract][Full Text] [Related]
39. Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer.
Jones JK; Thompson EM
Mol Cancer Ther; 2020 Sep; 19(9):1763-1769. PubMed ID: 32606014
[TBL] [Abstract][Full Text] [Related]
40. ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase.
Xiong YZ; Chen PY
J Mol Model; 2008 Nov; 14(11):1083-6. PubMed ID: 18663490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
